ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain
Trial ID or NCT#
The purpose of this enhanced surveillance study ("ESS") is to collect information regarding chronic adverse events that are possibly related to the ExAblate® System ("ExAblate") that are received by InSightec ("InSightec") following PMA approval. This study will examine adverse events reported in patients undergoing the device procedure for the first two years of commercial experience. Other relevant data may be collected as well.
A Post Approval Registry: ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain
Contact us to find out if this trial is right for you.